特朗普下达60天最后通牒，17家跨国药企面临降价压力｜快讯

Group 1 - The core action taken by President Trump involves demanding 17 leading global pharmaceutical companies to propose concrete plans to lower drug prices in the U.S. within 60 days, or face government intervention [3] - Trump's letter emphasizes the implementation of the "Most Favored Nation" pricing policy, which aims to link U.S. drug prices to lower prices in other countries [3] - According to RAND Corporation, the average price of prescription drugs in the U.S. is typically 2-3 times higher than in other developed countries, and can be up to 10 times higher in some cases [3] Group 2 - Following the pressure from the government, some pharmaceutical companies, such as AstraZeneca, have begun to adjust their strategies by announcing price reductions for certain drugs in the U.S. [4] - Companies like Eli Lilly, Novo Nordisk, and Pfizer are exploring direct sales models as a response to the ongoing pricing pressures [4] - The pharmaceutical industry is preparing for potential tariffs on imported drugs, indicating that the pricing issue is part of a larger political and corporate struggle [4]